Category Regulatory

Pilatus Biosciences to Present Sex-Specific CD36 Antibody Data in Colorectal Cancer at AACR 2026

Pilatus Biosciences to Showcase New Data on Sex-Specific Efficacy of CD36-Targeting Antibody in Colorectal Cancer at AACR 2026 Pilatus Biosciences has announced that it will present new preclinical findings at the upcoming AACR Annual Meeting 2026, scheduled to take place…

Read MorePilatus Biosciences to Present Sex-Specific CD36 Antibody Data in Colorectal Cancer at AACR 2026

Shionogi & Co., Ltd. Awarded U.S. Government Contract via BARDA Project BioShield for Drug-Resistant Bacterial Preparedness

Shionogi & Co., Ltd. Secures U.S. Government Contract via BARDA Project BioShield to Strengthen Preparedness Against Drug-Resistant Bacterial Threats Shionogi & Co., Ltd. has announced that its U.S.-based subsidiary, Shionogi Inc., has been awarded a significant federal contract under Biomedical…

Read MoreShionogi & Co., Ltd. Awarded U.S. Government Contract via BARDA Project BioShield for Drug-Resistant Bacterial Preparedness

United Therapeutics Corporation Receives U.S. Food and Drug Administration RMAT Designation for miroliverELAP® in Acute Liver Failure

United Therapeutics Corporation Receives U.S. Food and Drug Administration Regenerative Medicine Advanced Therapy (RMAT) Designation for miroliverELAP® in the Treatment of Acute Liver Failure United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation focused on developing innovative therapies for end-stage…

Read MoreUnited Therapeutics Corporation Receives U.S. Food and Drug Administration RMAT Designation for miroliverELAP® in Acute Liver Failure
VION Biosciences

VION Biosciences Completes Acquisition of CTL to Enhance Functional Immune Monitoring Capabilities

VION Biosciences Completes Acquisition of CTL, Bolstering Its Functional Immune Monitoring Capabilities VION Biosciences (“VION”), a life sciences company focused on building differentiated capabilities across research, diagnostics, and drug development workflows, has announced the successful completion of its acquisition of…

Read MoreVION Biosciences Completes Acquisition of CTL to Enhance Functional Immune Monitoring Capabilities
Oncology

Gilead to Acquire Tubulis, Boosting Oncology Pipeline with Next-Gen ADC Platform

Gilead to Acquire Tubulis to Enhance Oncology Portfolio with Potentially Best-in-Class ADC and Advanced Platform Gilead Sciences has announced that it has entered into a definitive agreement to acquire Tubulis GmbH, a Germany-based clinical-stage biotech specializing in next-generation antibody-drug conjugates…

Read MoreGilead to Acquire Tubulis, Boosting Oncology Pipeline with Next-Gen ADC Platform

TriSalus Life Sciences Appoints Richard Marshall, MD, as Chief Medical Officer

TriSalus Life Sciences Names Richard Marshall, MD, Chief Medical Officer TriSalus Life Sciences, a clinical-stage oncology company focused on integrating innovative drug delivery technologies with standard-of-care therapies and immunotherapeutic approaches, has announced the appointment of Richard Marshall, MD, as its…

Read MoreTriSalus Life Sciences Appoints Richard Marshall, MD, as Chief Medical Officer

ZIVO Bioscience inks commercial-scale manufacturing deal with Cyanotech Corporation for Zivolife™ algal biomass

ZIVO Bioscience Enters Large-Scale Manufacturing Partnership with Cyanotech Corporation to Produce Zivolife™ Algal Biomass Zivo Bioscience, Inc. (OTCQB: ZIVO), a research-driven biotech and agtech innovator specializing in therapeutic, medicinal, and nutritional products derived from proprietary algal cultures, has announced a…

Read MoreZIVO Bioscience inks commercial-scale manufacturing deal with Cyanotech Corporation for Zivolife™ algal biomass

Bridge Dental Group Expands Network with Addition of Foothill Family Dental Group and Peak Dental Specialists

Bridge Dental Group Strengthens Its Growing Network by Adding Foothill Family Dental Group and Peak Dental Specialists Bridge Dental Group has announced a significant expansion of its footprint in the United States through a new partnership with two well-established dental…

Read MoreBridge Dental Group Expands Network with Addition of Foothill Family Dental Group and Peak Dental Specialists

Clarametyx Biosciences Bolsters Executive Team to Drive Clinical Development Progress

Clarametyx Biosciences Enhances Leadership Team to Advance Clinical Development Initiatives Clarametyx Biosciences, Inc., a clinical-stage biotechnology company focused on developing immune-enabling therapies and vaccines to combat biofilm-driven chronic respiratory diseases, has announced key leadership promotions within its executive team. These…

Read MoreClarametyx Biosciences Bolsters Executive Team to Drive Clinical Development Progress